Funding Scientific Innovation: Global Investments in HIV Treatment Research and Development in 2010 and 2011

Development of new, simpler, more effective and affordable compounds will continue to be essential for attaining the goal of putting at least 15 million people on ART by 2015, as set forth in the 2011 Political Declaration on HIV and AIDS. To this end, pharmaceutical industry leaders moved seven compounds into phase III studies in 2010 and 2011, and seven compounds into phase II. The focus of development is on compounds that can be taken as a single pill once daily, thus simplifying treatment, improving adherence, and reducing the risk of stockout-induced resistance to individual drugs.